# Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis

> **NCT06058299** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Global Alliance for TB Drug Development** · enrollment: 309 (actual)

## Conditions studied

- Pulmonary TB
- Pulmonary Tuberculosis
- Drug Sensitive Tuberculosis

## Interventions

- **DRUG:** TBAJ-876
- **DRUG:** Pretomanid
- **DRUG:** Linezolid
- **DRUG:** Bedaquiline
- **DRUG:** HRZE
- **DRUG:** HR

## Key facts

- **NCT ID:** NCT06058299
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-24
- **Primary completion:** 2024-12-27
- **Final completion:** 2026-06
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06058299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06058299, "Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06058299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*